Q32 Bio Inc.
QTTBHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeQ32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven. The $257.5M market capitalization puts QTTB squarely in micro-cap range for its industry. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
Market Cap
$257.5M
Beta
-0.11
P/E (TTM)
2.75
P/E (Fwd)
-8.48
EPS (TTM)
$3.15
EPS (Fwd)
$-1.02
ROE
72.1%
ROA
14.7%
Cash
$106.3M
Total Debt
$5.3M
Free CF
$19.4M
52W Change
208.9%
Annual Financials
Cash vs Debt
Where QTTB stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, QTTB finished 26.16% below its 150-day moving average ($10.55) and 13.44% below its 200-day moving average ($9.00). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is QTTB overbought or oversold?
At the October 20, 2026 close, QTTB's RSI(14) was 28.6, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $106.3M in cash and $5.3M in debt, QTTB maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $19.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 72.1% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 14.7% further supports the picture of efficient asset utilization. Revenue has grown from $6.7M (2022) to $53.7M (2025), reflecting a 708% increase over the period.
With a beta below 0.7, Q32 Bio Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, QTTB has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing QTTB's risk profile alongside its fundamentals and technical indicators provides a more complete picture.